The management of microbial infection is one of the important issues for patients with acute myeloid leukemia (AML). They are considered to be at high risk for infection. They should be provided appropriate antimicrobial agents recommended by the Infectious Diseases Society of America (IDSA). Recently, there have been several significant changes in IDSA guidelines especially in the treatment of invasive fungal infection because of developments in several antifungal agents. This document constitutes the recommendations for the management of infection in patients with AML according to the updated guidelines of the IDSA. Evidence about infection control in AML is not enough in contrast to hematopoietic stem cell transplantation. Further studies are necessary to establish the strategy for microbial infections in AML.